# US 11,298,403 B2 · Therapeutic agent for inflammatory bowel disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,298,403 B2
- Document ID: US11298403B2
- Status: Granted
- Kind: B2
- Application number: 16/768,654
- Filed: 2018-11-30
- Published: 2020-12-10
- Granted: 2022-04-12
- Earliest claimed: 2017-12-01
- Assignees: Stemrim Inc.; Osaka University
- Applicants: StemRIM Inc.; Osaka University
- Inventors: Katsuto Tamai; Takashi Shimbo; Takehiko Yamazaki
- Web page: https://patentgrep.com/patent/US11298403B2

## CPC

- A61K 38/1709: {from mammals}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4702: {Regulators; Modulating activity}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present inventors discovered that an HMGB1 fragment peptide having a specific amino acid sequence exhibits an effect of suppressing weight loss and an effect of suppressing shortening of the large intestine and mucosal damage in an animal model of inflammatory bowel diseases. Based on these findings, pharmaceutical compositions for the prevention and/or treatment of inflammatory bowel diseases, which comprise the HMGB1 fragment peptide having the specific amino acid sequence are provided.

## Claims

### Claim 1

A method of treating an inflammatory bowel disease, comprising administering to a subject with the inflammatory bowel disease an effective amount of a substance described in any of following (a) to (b):
(a) a peptide consisting of the amino acid sequence described in SEQ ID NO: 1; and
(b) a peptide consisting of an amino acid sequence having 95% or more sequence identity with the amino acid sequence described in SEQ ID NO: 1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inflammatory bowel disease is a non-specific inflammatory bowel disease.

### Claim 3 (depends on 2)

The method of claim 2, wherein the non-specific inflammatory bowel disease is ulcerative colitis.

### Claim 4 (depends on 2)

The method of claim 2, wherein the non-specific inflammatory bowel disease is Crohn's disease.

### Claim 5

A method of suppressing weight loss or intestinal mucosal damage in a patient with an inflammatory bowel disease, comprising administering to the patient an effective amount of substance described in any of following (a) to (b):
(a) a peptide consisting of the amino acid sequence described in SEQ ID NO: 1;
(b) a peptide consisting of an amino acid sequence having 95% or more sequence identity with the amino acid sequence described in SEQ ID NO: 1.

### Claim 6 (depends on 5)

The method of claim 5, wherein the inflammatory bowel disease is a non-specific inflammatory bowel disease.